NIH Panel Endorse Active Monitoring for Men with Low-Risk Prostate Cancer

Share this article:

An independent panel convened by the National Institutes of Health (NIH) has recommended close monitoring rather than immediate treatment for men with localized, low-risk prostate cancer (PCa). Treatment can be delayed until warranted by disease progression.

The 14-member panel, which included authorities in cancer prevention, said approaches such as active surveillance have not been uniformly studied and available data do not suggest follow-up protocols. They recommended additional studies and standardized definitions to clarify optimal monitoring strategies.

Emerging consensus in the medical community defines low-risk PCa as a PSA level less than 10 ng/mL and a Gleason score of 6 or less, according to the panel. More than 100,000 PCa patients every year would undergo active monitoring instead of immediate treatment using this definition.

Framing of disease management options is an important factor in patient decision-making, and decisions should be highly individualized, the panel stated. Further recommendations endorsed registry-based cohort studies as well as multisite as opposed to single-institutional studies.

Share this article:
You must be a registered member of RUN to post a comment.

More in Prostate Cancer

Focal Prostate Cancer Therapy Safe, Feasible

Focal Prostate Cancer Therapy Safe, Feasible

In a study, none of the 62 men who had the treatment experienced erectile dysfunction or urinary incontinence.

MRI Highly Accurate in Detecting Significant Prostate Cancer

MRI Highly Accurate in Detecting Significant Prostate ...

Diffusion-weighted technique found to have a sensitivity and specificity of 89%-91% and 77%-81%, respectively.

BRCA2 Mutation Ups Prostate Cancer Death Risk

BRCA2 Mutation Ups Prostate Cancer Death Risk

In a study, the 12-year prostate cancer survival rate was 61.8% for men with the mutation versus 94.3% for those without it.